The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate
Open accessAbstract
Objective To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis.Design Randomized controlled trial.Setting Academic center.Patient(s) Ninety women with recurrent moderate or severe pelvic pain after unsuccessful conservative surgery for symptomatic rectovaginal endometriosis.Intervention(s) Twelve-month, continuous treatment with oral ethinyl E2, 0.01 mg, plus cyproterone acetate, 3 mg/day, or norethindrone acetate, 2.5 mg/day.Main outcome measure(s) Degree of satisfaction with therapy.Result(s) Seven women in the ethinyl E2 plus cyproterone acetate arm and five in the norethindrone acetate arm withdrew because of side effects (n=5), treatment inefficacy (n=6), or loss to follow-up (n=1). At 12 months, dysmenorrhea, deep dyspareunia, nonmenstrual pelvic pain, and dyschezia scores were substantially reduced without major between-group differences. Both regimens induced minor unfavorable variations in the serum lipid profile. According to an intention-to-treat analysis, 28 (62%) out of 45 patients in the ethinyl E2 plus cyproterone acetate group and 33 (73%) out of 45 in the norethindrone acetate group were satisfied with the treatment received.Conclusion(s) Low-dose norethindrone acetate could be considered an effective, tolerable, and inexpensive first-choice medical alternative to repeat surgery for treating symptomatic rectovaginal endometriotic lesions in patients who do not seek conception.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Low-dose NETA 2.5 mg/day orally is considered an effective, tolerable and inexpensive first choice for symptomatic rectovaginal endometriosis, significantly decreasing VAS scores for dysmenorrhea and dyspareunia [209].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [209]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas low-dose oral NETA is probably the best choice for rectovaginal lesions”
From “Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis (2011) · cites this paper as Vercellini et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reported response rates for therapy with 2.5 mg norethindrone acetate per day in endometriosis-associated pain range between 74 and 92%.”
From Pain and functional outcomes after surgical versus hormonal treatment in rectovaginal endometriosis: a retrospective cohort study (2026) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence for hormonal treatment specifically in RVE is less abundant and only one randomised-controlled trial was identified in the literature [29].”
From Pain and functional outcomes after surgical versus hormonal treatment in rectovaginal endometriosis: a retrospective cohort study (2026) · cites this paper as [29]
In the citing paper
“Based on our previous experience, the proportion of endometriosis patients satisfied with OC treatment is $65% (20,57).”
From A stepped-care approach to symptomatic endometriosis management: A participatory research initiative (2018) · cites this paper as [20]
In the citing paper
“Both treatments were equally effective in the management of pain symptoms and on the reduction of lesion size at ultrasound.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [13]
In the citing paper
“Overall, 73% women in the NETA group were satisfied or very satisfied with treatment compared to 62% in the EP group.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [13]
In the citing paper
“The lower dosage increases the tolerability, reducing weight gain and androgenic side effects, and limits the negative impact on serum cholesterol values [13].”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [13]
In the citing paper
“numerous studies by independent groups demonstrated the efficacy of a reduced daily dose of 2.5 mg [13-16].”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [13]
In the citing paper
“in Italy, the monthly cost of treatment with 2.5 mg/d is less than 2 US $ [13].”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised American Fertility Society Classification of Endometriosis: 1985
(1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48430-x · Cited by 1,803
Endometriosis and pelvic pain: relation to disease stage and localization
Vercellini, P., Trespidi, L., De Giorgi, O., Cortesi, I., Parazzini, F., & Crosignani, P. G. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58089-3 · Cited by 457
Self-citationUse of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290
Vercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289
Self-citationDosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Progestins for symptomatic endometriosis: a critical analysis of the evidence
Vercellini, P., Cortesi, I., & Crosignani, P. G. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00193-3 · Cited by 229
Self-citationLong-term follow-up after conservative surgery for rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Bettoni, G., & Gotsch, F. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2003.10.698 · Cited by 216
Deep Endometriosis: Definition, Pathogenesis, and Clinical Management
Vercellini, P., Frontino, G., Pietropaolo, G., Gattei, U., Daguati, R., & Crosignani, P. G. (2004) · The Journal of the American Association of Gynecologic Laparoscopists · doi:10.1016/s1074-3804(05)60190-9 · Cited by 180
Self-citationVercellini, P., De Giorgi, O., Mosconi, P., Stellato, G., Vicentini, S., & Crosignani, P. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02951-x · Cited by 180
Self-citationProlonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1
Surrey, E. S. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)01945-2 · Cited by 167
Cited by
Sorted by citations
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Self-citationZondervan, K. T., Becker, C. M., Koga, K., Missmer, S. A., Taylor, R. N., & Viganò, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0008-5 · Cited by 1,257
Systematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G. P., Ramilo, I. D. T. M., Roman, H., & Canis, M. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 378
The effect of surgery for symptomatic endometriosis: the other side of the story
Vercellini, P., Crosignani, P. G., Abbiati, A., Somigliana, E., Viganò, P., & Fedele, L. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn062 · Cited by 339
Self-citationHormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Metadata
- Authors
- Vercellini, P., Pietropaolo, G., De Giorgi, O., Pasin, R., Chiodini, A., & Crosignani, P. G.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Vercellini, Paolo
- ORCID
- Vercellini, Paolo
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 84
- Issue
- 5
- Pages
- 1375-1387
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2062896185
- Cited by
- 197
- References
- 28
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 8 · 2020: 13 · 2019: 6 · 2018: 18 · 2017: 13 · 2016: 9 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 15
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Fertility and Sterility (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- rectovaginal endometriosis, norethindrone acetate, ethinyl estradiol, cyproterone acetate, dysmenorrhea, dyspareunia, dyschezia, treatment satisfaction, lipid profile
- MeSH terms
- Norethindrone Acetate, Adolescent, Adult, Drug Therapy, Combination, Endometriosis, Estrogens, Female, Humans, Middle Aged, Norethindrone, Pain Measurement, Progestins, Rectal Diseases, Vaginal Diseases, Estrogen Replacement Therapy, Confidence Intervals, Statistics, Nonparametric
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
